Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Arrest | 5 | 2021 | 277 | 1.390 |
Why?
|
| Hypertrophy, Right Ventricular | 5 | 2013 | 33 | 1.320 |
Why?
|
| Dynamins | 3 | 2024 | 50 | 1.090 |
Why?
|
| Dichloroacetic Acid | 2 | 2017 | 11 | 1.020 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2024 | 58 | 0.880 |
Why?
|
| Mitochondria | 2 | 2020 | 553 | 0.800 |
Why?
|
| Hypertension, Pulmonary | 7 | 2015 | 354 | 0.800 |
Why?
|
| Myocardial Infarction | 1 | 2024 | 375 | 0.710 |
Why?
|
| Myocardial Stunning | 1 | 2020 | 12 | 0.700 |
Why?
|
| Electron Transport Complex I | 1 | 2020 | 30 | 0.690 |
Why?
|
| Superoxides | 1 | 2020 | 74 | 0.680 |
Why?
|
| Hydrogen Peroxide | 1 | 2020 | 158 | 0.660 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2017 | 13 | 0.590 |
Why?
|
| Hypothermia, Induced | 1 | 2017 | 82 | 0.560 |
Why?
|
| Glucose | 4 | 2021 | 629 | 0.540 |
Why?
|
| Mitochondrial Dynamics | 3 | 2024 | 56 | 0.440 |
Why?
|
| Xanthenes | 1 | 2012 | 23 | 0.420 |
Why?
|
| Glutamine | 1 | 2013 | 79 | 0.420 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2012 | 22 | 0.420 |
Why?
|
| Cardiopulmonary Resuscitation | 3 | 2021 | 222 | 0.410 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2012 | 33 | 0.410 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2012 | 73 | 0.410 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 171 | 0.390 |
Why?
|
| Rats | 10 | 2020 | 4040 | 0.360 |
Why?
|
| Heart Ventricles | 2 | 2013 | 779 | 0.360 |
Why?
|
| Reactive Oxygen Species | 3 | 2024 | 490 | 0.360 |
Why?
|
| Animals | 19 | 2024 | 27453 | 0.360 |
Why?
|
| Myocytes, Smooth Muscle | 4 | 2020 | 140 | 0.310 |
Why?
|
| Oxidation-Reduction | 4 | 2013 | 388 | 0.300 |
Why?
|
| Adaptation, Physiological | 1 | 2010 | 314 | 0.300 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 2020 | 241 | 0.290 |
Why?
|
| Myocytes, Cardiac | 3 | 2024 | 314 | 0.290 |
Why?
|
| Mice, Inbred C57BL | 6 | 2021 | 3228 | 0.290 |
Why?
|
| Mice | 8 | 2024 | 11812 | 0.280 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2015 | 1237 | 0.280 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2021 | 142 | 0.260 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2024 | 25 | 0.230 |
Why?
|
| Mitochondria, Heart | 1 | 2024 | 50 | 0.220 |
Why?
|
| Hypoxia | 3 | 2020 | 654 | 0.210 |
Why?
|
| Vascular Remodeling | 2 | 2020 | 22 | 0.210 |
Why?
|
| GTP Phosphohydrolases | 2 | 2013 | 74 | 0.200 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 2375 | 0.200 |
Why?
|
| Random Allocation | 2 | 2020 | 327 | 0.200 |
Why?
|
| Mitochondrial Proteins | 2 | 2013 | 127 | 0.190 |
Why?
|
| Homeostasis | 1 | 2024 | 417 | 0.190 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2019 | 66 | 0.180 |
Why?
|
| Familial Primary Pulmonary Hypertension | 4 | 2013 | 60 | 0.180 |
Why?
|
| Heart Failure | 1 | 2010 | 1191 | 0.180 |
Why?
|
| Receptors, Prostaglandin | 1 | 2020 | 7 | 0.180 |
Why?
|
| Hemodynamics | 2 | 2017 | 731 | 0.180 |
Why?
|
| Fatty Acids | 2 | 2011 | 134 | 0.180 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 29 | 0.180 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 136 | 0.170 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2019 | 27 | 0.160 |
Why?
|
| Calcium | 1 | 2024 | 1178 | 0.160 |
Why?
|
| Neointima | 1 | 2018 | 14 | 0.150 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2018 | 19 | 0.150 |
Why?
|
| Femoral Artery | 1 | 2018 | 84 | 0.150 |
Why?
|
| Quinazolinones | 2 | 2015 | 15 | 0.150 |
Why?
|
| Cell Proliferation | 4 | 2020 | 1668 | 0.140 |
Why?
|
| Down-Regulation | 2 | 2020 | 520 | 0.130 |
Why?
|
| Receptors, Prostaglandin E, EP3 Subtype | 1 | 2015 | 1 | 0.120 |
Why?
|
| Positron-Emission Tomography | 2 | 2021 | 337 | 0.120 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2015 | 55 | 0.120 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2015 | 89 | 0.120 |
Why?
|
| Cell Movement | 1 | 2018 | 785 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1705 | 0.110 |
Why?
|
| Diazooxonorleucine | 1 | 2013 | 5 | 0.110 |
Why?
|
| Cells, Cultured | 3 | 2015 | 2884 | 0.110 |
Why?
|
| Survival Rate | 1 | 2017 | 1886 | 0.110 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2013 | 45 | 0.110 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2012 | 24 | 0.110 |
Why?
|
| Physical Conditioning, Animal | 1 | 2012 | 19 | 0.110 |
Why?
|
| Dobutamine | 1 | 2012 | 61 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2013 | 126 | 0.100 |
Why?
|
| Female | 6 | 2021 | 46328 | 0.100 |
Why?
|
| Mitochondria, Muscle | 1 | 2012 | 27 | 0.100 |
Why?
|
| Cardiotonic Agents | 1 | 2012 | 89 | 0.100 |
Why?
|
| Heat-Shock Proteins | 1 | 2013 | 183 | 0.100 |
Why?
|
| Male | 9 | 2021 | 42438 | 0.100 |
Why?
|
| Mitosis | 1 | 2012 | 152 | 0.100 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2012 | 113 | 0.100 |
Why?
|
| Myocardial Contraction | 1 | 2012 | 252 | 0.100 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2010 | 3 | 0.090 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2012 | 136 | 0.090 |
Why?
|
| Dopamine | 1 | 2012 | 276 | 0.090 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2010 | 32 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 184 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 265 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 693 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2012 | 725 | 0.090 |
Why?
|
| Pulmonary Artery | 3 | 2020 | 320 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2013 | 678 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2010 | 466 | 0.080 |
Why?
|
| Humans | 10 | 2021 | 89500 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2015 | 3392 | 0.070 |
Why?
|
| Macrophages | 1 | 2010 | 574 | 0.070 |
Why?
|
| Cell Hypoxia | 2 | 2019 | 171 | 0.070 |
Why?
|
| Models, Biological | 1 | 2013 | 1762 | 0.070 |
Why?
|
| Radiopharmaceuticals | 2 | 2021 | 195 | 0.060 |
Why?
|
| Oxygen | 1 | 2010 | 743 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2013 | 1658 | 0.060 |
Why?
|
| Antihypertensive Agents | 2 | 2020 | 251 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1982 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2020 | 2003 | 0.050 |
Why?
|
| Glycolysis | 2 | 2012 | 135 | 0.050 |
Why?
|
| Microglia | 1 | 2021 | 108 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2021 | 293 | 0.040 |
Why?
|
| Hypertrophy | 1 | 2020 | 67 | 0.040 |
Why?
|
| Epoprostenol | 1 | 2020 | 46 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 97 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2020 | 108 | 0.040 |
Why?
|
| Sirolimus | 1 | 2020 | 162 | 0.040 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2019 | 46 | 0.040 |
Why?
|
| Protein Transport | 1 | 2019 | 421 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 1 | 2019 | 255 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2019 | 646 | 0.030 |
Why?
|
| Lung | 2 | 2013 | 1270 | 0.030 |
Why?
|
| Aconitate Hydratase | 1 | 2015 | 11 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 976 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 136 | 0.030 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2015 | 85 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 272 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2015 | 127 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2020 | 2021 | 0.030 |
Why?
|
| Optic Atrophy, Autosomal Dominant | 1 | 2013 | 4 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2013 | 16 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 245 | 0.030 |
Why?
|
| Exercise Tolerance | 1 | 2013 | 54 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 2578 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2015 | 317 | 0.030 |
Why?
|
| Monocrotaline | 1 | 2012 | 13 | 0.030 |
Why?
|
| Cyclin B1 | 1 | 2012 | 18 | 0.030 |
Why?
|
| Cobalt | 1 | 2012 | 30 | 0.030 |
Why?
|
| Inflammation | 1 | 2018 | 975 | 0.030 |
Why?
|
| CDC2 Protein Kinase | 1 | 2012 | 46 | 0.030 |
Why?
|
| Ranolazine | 1 | 2011 | 4 | 0.020 |
Why?
|
| Trimetazidine | 1 | 2011 | 3 | 0.020 |
Why?
|
| Acetanilides | 1 | 2011 | 6 | 0.020 |
Why?
|
| Serine | 1 | 2012 | 104 | 0.020 |
Why?
|
| Hexokinase | 1 | 2011 | 19 | 0.020 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2011 | 20 | 0.020 |
Why?
|
| Glycogen | 1 | 2011 | 59 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 156 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 245 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 376 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2011 | 145 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2010 | 66 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2010 | 88 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 696 | 0.020 |
Why?
|
| Brain | 1 | 2021 | 2292 | 0.020 |
Why?
|
| Arteriovenous Malformations | 1 | 2010 | 45 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 123 | 0.020 |
Why?
|
| Ventricular Function, Right | 1 | 2011 | 146 | 0.020 |
Why?
|
| Transfection | 1 | 2012 | 909 | 0.020 |
Why?
|
| Piperazines | 1 | 2011 | 282 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2012 | 371 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1130 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 405 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 642 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1860 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 1462 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1716 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1226 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 2762 | 0.020 |
Why?
|
| Time Factors | 1 | 2012 | 5330 | 0.010 |
Why?
|